NCT00263965View on ClinicalTrials.gov

ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity

PHASE2TerminatedINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

August 31, 2005

Study Completion Date

July 31, 2006

Conditions

Type 2 Diabetes

Interventions

DRUG

Tesaglitazar

DRUG

Metformin

BEHAVIORAL

Dietary and lifestyle modification counseling

Trial Locations (3)

Unknown

Research Site, Helsinki

Research Site, Pisa

Research Site, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY